Chester A. Mathis | |
|---|---|
| Education | Humboldt State University B.Sc. (1972) UC Davis Ph.D. (1979) |
| Awards | Metlife Foundation Award for Medical Research in Alzheimer's Disease[1] (2004) Potamkin Prize (2008) Reagan Institute Award (2009) |
| Scientific career | |
| Institutions | University of Pittsburgh Medical Center |
Chester Mathis is an American chemist who is currently the Distinguished Professor of Radiology at University of Pittsburgh and holds the UPMC Endowed Chair of PET Research.[2][3][4]
He is known for is work with William E. Klunk on a PET radiotracer for imaging amyloid, a protein linked to neurodegenerative diseases including Alzheimer’s. His efforts led to the creation of a novel category of high-efficacy radiopharmaceutical agents, for example Pittsburgh Compound-B (PiB), which can be used to assess beta-amyloid in the living human brain using PET scanning, and which is a fluorescent analog of thioflavin T.[3] For his work on Alzheimer's disease he has received the Metlife Foundation Award (2004)[5] and the Potamkin Prize (2008).[6]
References
- ↑ "MetLife Foundation Awards for Medical Research in Alzheimer's Disease" (PDF). Archived from the original (PDF) on 13 October 2018.
- ↑ "Distinguished Professor". pitt.edu. Retrieved May 4, 2017.
- 1 2 "Chester Mathis". Retrieved May 4, 2017.
- ↑ "Chester Mathis". pharmacology.us. Retrieved May 4, 2017.
- ↑ "2016 Metlife Foundation Awards for Medical Research in Alzheimer's Disease" (PDF). Metlife Foundation. Archived from the original (PDF) on 13 October 2018. Retrieved 18 October 2018.
- ↑ "Awards History". American Academy of Neurology. 23 September 2017. Archived from the original on 23 September 2017. Retrieved 31 October 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.